Despite a lower response observed for the variant spike proteins, we report evidence of a sustained humoral response against native, B.1.351, B.1.617.2 and P.1 variant spike proteins among non-hospitalized Canadian adults. Antibody levels and pseudo-neutralization of the ectodomain of SARS-CoV-2 spike protein/human ACE-2 receptor interaction were analyzed with native, B.1.351, B.1.617.2 and P.1 variant spike proteins. Sera were collected 4 and 16 weeks post-diagnosis. Thirty-two SARS-CoV-2-positive (PCR-confirmed) and non-hospitalized Canadian adults were enrolled 14–21 days post-diagnosis in 2020, before the emergence of the B.1.351 (also known as Beta), B.1.617.2 (Delta) and P.1 (Gamma) VOCs. Characterizing the cross-reactivity of antibodies against these VOCs is necessary to understand the humoral response of non-hospitalized individuals previously infected with SARS-CoV-2, a population that remains understudied. This work entitled "Rapid lateral flow immunoassay for the fluorescence detection of SARS-CoV-2 RNA" was published in Nature Biomedical Engineering on December 3rd, 2020.SARS-CoV-2 variants of concern (VOCs) have emerged worldwide, with implications on the spread of the pandemic. "We are confident that the HC-FIA test is capable of serving as a sure safeguard in containing the epidemic through reducing community spread and imported cases, especially in developing countries," said WANG Daming, lead researcher of the study. It can function as a "suitcase laboratory" and thus be used as an on-site detection method for outpatient departments, emergency departments, customs and grassroots disease control. The test kit requires little in terms of equipment and professional personnel to confirm infection. The test kit was recently approved by the National Medical Products Administration and received European Conformity certification. The current research not only represents proof-of-concept, but also has resulted in development of a commercial test kit for the diagnosis of SARS-CoV-2. The HC-FIA process described here was supported by a multi-hospital randomized double-blind trial involving 734 samples. This assay and test kit can also be adapted for the detection of other viral RNA. The performance of the HC-FIA detection reagent is free of interference by hemoglobin, mucin and various possible drugs that might exist in clinical samples. In addition, no significant cross-reaction has been found between the SARS-CoV-2 probes and 55 common pathogens. It can achieve a limit of detection of 500 copies/mL, comparable to commercial kits based on real-time quantitative polymerase chain reaction (qPCR). The process uses optimized DNA probes to target the conserved open reading frame 1ab, envelope protein and the nucleocapsid regions of the SARS-CoV-2 genome derived from clinical throat swab samples. The whole test procedure involves two steps, namely hybridization and immunofluorescence analysis, and it can be finished in less than an hour. The use of the monoclonal antibody S9.6 is the distinctive feature of this process, which recognizes DNA-RNA double-stranded hybrids and enables the conversion of nucleic acid testing into immunofluorescence on a simple lateral flow dipstick. To meet this need, scientists from the Suzhou Institute of Biomedical Engineering and Technology have developed a novel amplification-free rapid SARS-CoV-2 nucleic acid detection platform based on hybrid capture fluorescence immunoassay (HC-FIA). The COVID-19 pandemic has highlighted the need for rapid and accurate nucleic acid detection at the point of care. f, Probe distribution in the genome of SARS-CoV-2. Step 2: determination of the intensity of the fluorescence signals on the test card using the device shown in c. Step 1: nucleic acid hybridization in an incubator at constant temperature. e, The testing process of the HC-FIA assay. d, A photograph of the portable suitcase laboratory, which has a length of 55.5?cm, a width of 37?cm and a height of 23?cm, with a weight of 8.5?kg. b, Representative results on a lateral flow strip.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |